| Date: | 2022-04-10 | |
|----------------|---|----------|
| Your Na | ame: Nanjin Chen | |
| Manusc | cript Title: Estimation of the median effective dose and the 95% effective dose of alfentanil req | uired to |
| <u>inhibit</u> | the bronchoscopy reaction during painless bronchoscopy with i-gel supraglottic airway devi | ice: An |
| Up-and | d-Down Sequential Allocation Trial | |
| Manusc | cript number (if known): | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | None | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | |
| | | | |
| | | | |
| 4 | Consulting fees | None | |

| | | | 1 |
|----|------------------------------|--------|---|
| | | | |
| | | | |
| 5 | Payment or honoraria for | None | |
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | None | |
| | testimony | | |
| | | | |
| 7 | Support for attending | None | |
| | meetings and/or travel | | |
| | , , , , , , , , | | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | None | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | None | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | None | |
| | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | None | |
| 12 | materials, drugs, medical | 140110 | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | None | |
| 13 | financial interests | Notice | |
| | inianciai interests | | |
| | | | |
| | | | |
| | | | |

| The author | has no conflicts | of interest to d | leclare. | | |
|------------|------------------|------------------|----------|--|--|
| | | | | | |
| | | | | | |

Please place an "X" next to the following statement to indicate your agreement:

| Date: | _ 2022-04-10 | |
|-------------------|--|-----------|
| Your Name | e: Xiaodan Wang | |
| Manuscrip | ot Title: Estimation of the median effective dose and the 95% effective dose of alfentanil req | quired to |
| <u>inhibit th</u> | e bronchoscopy reaction during painless bronchoscopy with i-gel supraglottic airway devi | ice: An |
| Up-and-I | Down Sequential Allocation Trial | |
| Manuscrip | ot number (if known): | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | None | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | |
| | | | |
| | | | |
| 4 | Consulting fees | None | |

| 5 | Payment or honoraria for | None | |
|----|---|------|--|
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | A. | |
| 6 | Payment for expert | None | |
| | testimony | | |
| 7 | Support for attending | None | |
| , | meetings and/or travel | None | |
| | g , | | |
| | | | |
| 8 | Patents planned, issued or | None | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | None | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy | None | |
| | | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| | ototi. Si stoti. options | 1.19 | |
| | | | |
| 12 | Receipt of equipment, | None | |
| | materials, drugs, medical | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | None | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |

| The author has no conflicts of interest to declare. |
|---|
| |
| |
| |

Please place an "X" next to the following statement to indicate your agreement:

| Date:_ | _2022-04-10 |
|---------|---|
| Your N | ame: Lingyang Chen |
| Manus | cript Title: Estimation of the median effective dose and the 95% effective dose of alfentanil required to |
| inhibit | the bronchoscopy reaction during painless bronchoscopy with i-gel supraglottic airway device: An |
| Up-an | d-Down Sequential Allocation Trial |
| Manus | cript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | None | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | |
| | | | |
| | | | |
| 4 | Consulting fees | None | |

| 5 | Payment or honoraria for | None | |
|----|---|------|--|
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | A. | |
| 6 | Payment for expert | None | |
| | testimony | | |
| 7 | Support for attending | None | |
| , | meetings and/or travel | None | |
| | g , | | |
| | | | |
| 8 | Patents planned, issued or | None | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | None | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy | None | |
| | | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| | ototi. Si stoti. options | 1.15 | |
| | | | |
| 12 | Receipt of equipment, | None | |
| | materials, drugs, medical | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | None | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |

| The author has no conflicts of interest to declare. |
|---|
| |
| |
| |

Please place an "X" next to the following statement to indicate your agreement:

| Date: | 2022-04-10 |
|------------------|---|
| Your Nar | me: Mingcang Wang |
| Manuscr | ipt Title: Estimation of the median effective dose and the 95% effective dose of alfentanil required to |
| <u>inhibit t</u> | the bronchoscopy reaction during painless bronchoscopy with i-gel supraglottic airway device: An |
| Up-and | -Down Sequential Allocation Trial |
| Manuscr | ipt number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | None | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | |
| | | | |
| | | | |
| 4 | Consulting fees | None | |

| 5 | Payment or honoraria for | None |
|----|---|------|
| | lectures, presentations, speakers bureaus, | |
| | | |
| | manuscript writing or | |
| | educational events | |
| 6 | Payment for expert | None |
| | testimony | |
| | | |
| 7 | Support for attending meetings and/or travel | None |
| | | |
| | | |
| 8 | Patents planned, issued or | None |
| | pending | |
| | | |
| 9 | Participation on a Data Safety Monitoring Board or | None |
| | | |
| | Advisory Board | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy | None |
| | | |
| | | |
| | group, paid or unpaid | |
| 11 | Stock or stock options | None |
| | | |
| | | |
| 12 | Receipt of equipment, materials, drugs, medical | None |
| | | |
| | writing, gifts or other services | |
| 13 | Other financial or non- financial interests | None |
| | | |
| | | |
| | | |

| The author has no conflicts of interest to declare. |
|---|
| |
| |

Please place an "X" next to the following statement to indicate your agreement:

| Date: | _ 2022-04-10 |
|-------------------|---|
| Your Name | e:Yongpo Jiang |
| Manuscrip | t Title: Estimation of the median effective dose and the 95% effective dose of alfentanil required to |
| <u>inhibit th</u> | e bronchoscopy reaction during painless bronchoscopy with i-gel supraglottic airway device: An |
| Up-and-E | Down Sequential Allocation Trial |
| Manuscrip | t number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | None | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | |
| | | | |
| | | | |
| 4 | Consulting fees | None | |

| 5 | Payment or honoraria for | None | |
|----|---|------|--|
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| _ | educational events | | |
| 6 | Payment for expert | None | |
| | testimony | | |
| 7 | Compant for attending | Nana | |
| / | Support for attending meetings and/or travel | None | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | None | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | None | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role in other board, society, | None | |
| | | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid | Nama | |
| 11 | Stock or stock options | None | |
| | | | |
| 12 | Receipt of equipment, | None | |
| 12 | materials, drugs, medical writing, gifts or other | None | |
| | | | |
| | services | | |
| 13 | Other financial or non- | None | |
| | financial interests | | |
| | | | |
| _ | | | |
| | | | |

| The author has no conflicts of interest to declare. |
|---|
| |
| |
| |

Please place an "X" next to the following statement to indicate your agreement: